Seres Therapeutics, Inc.

Seres Therapeutics reported a net income of $4.6 million for the second quarter of 2026, a significant improvement from a net loss of $19.9 million in the prior year, primarily driven by a $25 million gain from a Milestone Termination Payment from Nestlé. The company also announced positive topline results from an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC), with 80% of participants achieving an immunosuppressive-free clinical response. Additionally, Seres is taking further actions to reduce ongoing facility costs, including terminating a lease, and expects to fund operations through Q1 2027.

Seres Therapeutics, Inc. entered into a Third Amendment to Lease and Termination Agreement to effect an early termination of one of its leases, significantly reducing ongoing annual facilities costs and materially eliminating primary restoration obligations. The agreement involves surrendering approximately 21,295 rentable square feet and shortening the lease term for the remaining 47,341 square feet to December 31, 2026. As consideration, Seres will pay a $3.85 million termination fee, increase a letter of credit by $2.2 million, and issue common stock valued at $0.5 million.

Seres Therapeutics, Inc. reconvened its 2026 Annual Meeting of Stockholders, where all proposals were approved. Stockholders voted to amend and restate the 2025 Incentive Award Plan, increasing the number of shares available for issuance by 900,000. Additionally, three Class II directors were elected, PricewaterhouseCoopers LLP was ratified as the independent auditor for 2026, and the compensation of named executive officers received advisory approval.

Seres Therapeutics announced encouraging top-line results from an Investigator-Sponsored Trial (IST) evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis (irEC). The study showed that 80% of SER-155 recipients achieved an immunosuppressive-free clinical response at Day 15, with 33% achieving complete clinical remission. The drug was well-tolerated, with no drug-related serious adverse events, and pharmacology data supported its mechanism of action, suggesting potential for expansion into other inflammatory and immune diseases. Seres is now seeking partners for SER-155 in irEC and funding for its broader pipeline.

Seres Therapeutics announced it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155. The trial focuses on patients with immune checkpoint inhibitor-related enterocolitis (irEC), a serious side effect of cancer therapy. The webcast is scheduled for July 8, 2026, at 8:30 am ET, and will detail SER-155's potential as an immunosuppressive-free treatment to prevent interruption of cancer therapy. The IST involved 15 participants with moderate to severe irEC, with a primary endpoint of immunosuppressive-free clinical response by Day 15.

Seres Therapeutics announced two transactions to strengthen its balance sheet and extend its cash runway. The company will receive $25 million from Nestlé Health Science in two installments by October 2026, buying out potential future VOWST™ net sales-based milestones. Additionally, Seres restructured its lease agreement for its Cambridge, MA facility, reducing its leased space by approximately 45,832 square feet and decreasing long-term lease obligations by about $33.9 million. These actions are projected to extend the company's operating cash runway well into the first quarter of 2027.

Seres Therapeutics announced two transactions to strengthen its balance sheet and extend its operating cash runway well into Q1 2027. Nestlé Health Science will pay Seres $25 million in two installments in 2026 to buy out potential future VOWST net sales-based milestones. Additionally, Seres restructured a lease agreement for one of its facilities, significantly reducing leased space, annual cash costs, and long-term lease obligations. The company also anticipates clinical data from an investigator-sponsored SER-155 study later this month.

Seres Therapeutics, Inc. announced that Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors, effective May 31, 2026. Dr. Woerle also resigned from the committees on which he served. The company stated that his departure was not due to any disagreement with Seres Therapeutics' operations, policies, or practices.

Seres Therapeutics, Inc. announced that its management will attend and present a company overview at the H.C. Wainwright 4th Annual BioConnect Investor Conference. The presentation is scheduled for May 19, 2026, at 3:30 p.m. ET, with a live webcast accessible via the company's website. Seres Therapeutics is a clinical-stage biotechnology company focused on inflammatory and immune diseases, known for developing VOWST and advancing pipeline candidates like SER-155 and SER-603.

Seres Therapeutics reported a net loss of $(19.9) million for the first quarter of 2026, a significant decline from a net income of $32.7 million in the prior year, largely due to the absence of the VOWST Business sale gain. The company's cash and cash equivalents fell to $29.8 million, leading management to conclude that substantial doubt exists regarding its ability to continue as a going concern. In response, Seres implemented cost reduction measures, including a 30% workforce reduction, and has paused further investment in its SER-155 Phase 2 study while actively seeking additional funding.